Telomerase inhibitors for the treatment of cancer: The current perspective

Expert Opinion on Investigational Drugs

Volumn 10, Issue 12, 2001, Pages 2141-2156

  Perry, P J ^a   Arnold, J R P ^a   Jenkins, T C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Antisense; Cancer; Chemotherapy; G quadruplex; hTERT; Oligonucleotide; Reverse transcriptase inhibitor; Ribozyme; RNA; Telomerase; Telomerase inhibitor; Telomere; Tetraplex DNA

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; ALKALOID DERIVATIVE; ALTERPERYLENOL; ANTISENSE OLIGODEOXYNUCLEOTIDE; BERBERINE DERIVATIVE; BETA RUBRAMYCIN; BISINDOLYLMALEIMIDE; CATECHIN; CERAMIDE DERIVATIVE; CRM 646 A; DNA; FJ 5002; GAMMA RUBROMYCIN; GRISEORHODIN A; GRISEORHODIN C; HOLOENZYME; HOMOHARRINGTONINE; MESSENGER RNA; NUCLEIC ACID; PROTEIN; PURPUROMYCIN; QUINOLINE DERIVATIVE; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPHINGOSINE DERIVATIVE; STAUROSPORINE DERIVATIVE; TELOMERASE; TELOMERASE INHIBITOR; THIELAVIN B; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL IMMORTALIZATION; CELL PROLIFERATION; CHROMOSOME; CONTROLLED STUDY; DNA STRUCTURE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME SUBSTRATE; EUKARYOTE; GENETIC STABILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN NUCLEIC ACID INTERACTION; REVIEW; SOMATIC CELL; TELOMERE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 0035217744     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.12.2141     Document Type: Review

References (95)

1. Recent advances in the development of telomerase inhibitors for the treatment of cancer
2. Telomerase inhibitors: Targeting the vulnerable end of cancer?
3. Telomerase: A therapeutic target for the third millenium
4. Telomerase and cancer
5. Switching and signalling at the telomere
6. DNA tetraplex-binding drugs: Structure-selective targeting is critical for antitumour telomerase inhibition
7. The design of telomerase inhibitors for the treatment of cancer
8. Secondary structure of vertebrate telomerase RNA
9. Identification of functional domains and dominant negative mutations in vertebrate telomerase RNA using an in vivo reconstitution system
10. The telomerase RNA pseudoknot is critical for the stable assembly of a catalytically active ribonucleoprotein
11. Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase
12. Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions
13. Human telomerase RNA-protein interactions
14. A stem-loop of Tetrahymena telomerase RNA distant from the template potentiates RNA folding and telomerase activity
15. Human telomerase contains two co-operating telomerase RNA molecules
16. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumour cell proliferation
17. Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma
18. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium
19. Catalytic subunit of telomerase expression is related to RNA component expression
20. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure
21. Algorithms and thermodynamics for RNA secondary structure prediction: A practical guide
22. The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells
23. Controlling gene expression with 2-5A antisense
24. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas
25. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component
26. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA
27. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas
28. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53
29. 2-5A Antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells
30. Specific inhibition of human telomerase activity by transfection agent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells
31. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection agent, FuGENE6, in HeLa cells
32. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
33. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: Effect of length, phosphorothioate substitution and time inside cells
34. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
35. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed cells
36. Clinical studies of antisense therapy in cancer
37. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity
38. Ribozyme cleavage of telomerase mRNA sensitises breast cancer cells to inhibitors of topoisomerase
39. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
40. The effects of nucleoside analogues on telomerase and telomeres in Tetrahymena
41. Blockade of telomerase function in various cells
42. Interaction of deoxyguanosine nucleotide analogues with human telomerase
43. Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogues: Potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate
44. Targeting multi-stranded DNA structures
45. G-quadruplex DNA structures-variations on a theme
46. Structures and properties of multi-stranded nucleic acids
47. Determinants of DNA quadruplex structural type: Sequence and potassium binding
48. Structures of the potassium-saturated, 2:1, and intermediate, 1:1, forms of a quadruplex DNA
49. 205Tl NMR
50. +: The cation programs enantiomeric self-recognition
51. 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation
52. Are guanine tetrads stabilised by bifurcated hydrogen bonds?
53. Structural dynamics and cation interactions of DNA quadruplex molecules containing mixed guanine/cytosine quarters revealed by large-scale MD simulations
54. 7 quadruplex structures: Effect of the coordinated cations
55. NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA
56. G-quadruplex DNA: A target for drug design
57. G-quadruplexes as targets for drug design
58. G-quadruplex DNA: A potential target for anti-cancer drug design
59. Accelerated assembly of G-quadruplex structures by a small molecule
60. Inhibition of unwinding of G-quadruplex structures by Sgs1 helicase in the presence of N,N-bis[2-(1-piperidine)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand
61. Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule
62. DNA tetraplex formation in the control region of c-myc
63. Design and synthesis of the G-quadruplex-specific cleaving reagent perylene-EDTA·iron(II)
64. Oxidative damage generated by an oxo-metalloporphyrin onto the human telomeric sequence
65. A DNA-porphyrin minor-groove complex at atomic resolution: The structural consequences of porphyrin ruffling
66. Selective interactions of cationic porphyrins with G-quadruplex structures
67. Porphyrins can catalyse the interconversion of DNA quadruplex structural types
68. Synthesis of mono- and bis-substituted anthraquinones as inhibitors of human telomerase
69. Molecular modelling and cytotoxicity of substituted anthraquinones as inhibitors of human telomerase
70. Sequence and structural selectivity of nucleic acid binding ligands
71. Structural characterisation of a guanine-quadruplex ligand complex
72. Molecular modelling studies on G-quadruplex complexes of telomerase inhibitors: Structure-activity relationships
73. Human telomerase inhibition by substituted acridine derivatives
74. Telomerase: Biology and Phase I trials
75. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors
76. A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline
77. Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes
78. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay
79. Fluorescence resonance energy transfer as a probe for G-quartet formation by a telomeric repeat
80. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus
81. 3] G-tetraplex
82. The Frank Rose Memorial Lecture: Targeting nuclear protein complexes in cancer cells for selective cancer therapeutics
83. Inhibition of human telomerase by rubromycins: Implication of spiroketal system of the compounds as an active moiety
84. Inhibition of human telomerase activity by alterperylenol
85. Inhibition of telomerase activity by fungus metabolites CRM646-A and thielavin B
86. Inhibition of telomerase by homoharringtonine induces apoptosis in a human Burkitt lymphoma cell line
87. Inhibition of telomerase by tea catechins: A mechanism for tea anticancer and chemopreventative effects
88. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture
89. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells
90. Development of novel telomerase inhibitors based on a bisindole unit
91. Identification of a series of potent telomerase inhibitors using a time-resolved fluorescence-based assay
92. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro
93. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-orientated screening program with COMPARE analysis
94. Pt(II) complexes with different N-donor aromatic ligands for specific inhibition of telomerase
95. Targeting RNA with small-molecule drugs: Therapeutic promise and chemical challenge